C and of high TG, [13] [14] [15] [16] which has been suggested as a partial explanation for their increased CHD risk. 5, 6 Chinese have lower levels of low-density lipoprotein cholesterol (LDL-C) and TG [16] [17] [18] and Japanese have higher levels of HDL-C 16 compared to NHWs, which may help explain the lower risk of CHD in these Asian subgroups. The American Heart Association, 22 the US Department of Health and Human Services, 23 and the Institute of Medicine 24 have all acknowledged that national vital statistics data for racial/ethnic minority populations must be supplemented with population-based, local-level data in order to inform and guide the development, implementation, and evaluation of programs to address health disparities. Despite known heterogeneity in CVD risk among racial/ethnic subgroups, no studies have comprehensively examined the prevalence of dyslipidemia subtypes and treatment across the major racial/ethnic groups in the US. The primary aim of this study was to identify racial/ethnic differences in dyslipidemias in order to guide prevention, detection, and treatment efforts.
Methods

Setting
This study was conducted in a mixed-payer, outpatient health care organization serving approximately 800,000 active patients in northern California, which has been using the EpicCare electronic health record (EHR) system since 2000. This health care organization is unique among large clinical data resources because more than 30% of the overall patient population selfidentifies as Asian American. The demographic characteristics of the patients are generally similar to those of residents in the surrounding service area (Alameda, San Mateo, and Santa Clara counties). The patient population is insured (58% preferred provider organization (PPO), 23% health maintenance organization (HMO), 16% Medicare, 2% self-pay, and 1% Medicaid), LDL-C to avoid missing treated patients with controlled LDL-C after initial analyses indicated that using only laboratory data produced prevalence rates below those found in national data 27 , and that treatment rates differed by subgroup. Treatment with other LMAs (fibric acid derivatives, niacin, and omega 3 fish oil) was not included in the definition of high LDL-C, low HDL-C, or high TG, as they are not specific to one dyslipidemia subtype, 10 results >6.5%, fasting blood glucose results >126 mg/dL, random blood glucose >200 mg/dL, or oral glucose tolerance test >200 mg/dL) 28 or use of any anti-diabetic medications.
Statistical Methods
For our primary race/ethnic subgroup comparisons we calculated age-adjusted prevalence rates of dyslipidemia subtypes (high LDL-C, low HDL-C, and high TG) among men and women using direct standardization to the NHW population. Broad age categories (35-44, 45-54, 55-64, 65- 74, 75+ (years) were used to achieve stratum-specific rates for direct standardization.
Categorical variables (Table 1) were compared using pairwise chi-square tests, and non- te es wa wa was s id id iden enti ti ifi fi ied ed u us sing g g I IC CD--9 -9 cod od de es es ( ( (25 25 50. 0 X0 X0 X0, 25 250. 0 X X2 X2) ) ) o or or t tw wo wo a a abn bn bnor or orma ma al gl gluc uc ucos os ose e e me me eas as asur urem em men ent ts s a a acc ccor rdi di d ng ng ng t t to o o Am Am mer er eric ic ican an n D D Di i b ab abet e e e es A A As ss ssoc oc ocia ia i t ti t on on on g gu u uid de deli li ine ne n s s s (h (h (hem em emog og glo o obi bin n n A A1 A1c esults >6.5%, %, %, f f fas as sti ti t ng ng ng b b blo l od od od g g glu u uco co cose se e res es esul ul ults ts ts > > >12 12 26 6 6 m m mg/ g/ g dL dL L, , ra ra rand nd ndom om om b b blo lo lood od od g g glu lu luco co ose se se > > >20 20 200 0 mg/dL, or r r groups that did not follow a normal distribution. Odds ratios were calculated using multivariable logistic regression adjusting for patient age, BMI, and smoking status. In secondary analyses we examined prevalence rates stratifying patients with and without a history of vascular disease. We also conducted additional analyses adjusting the model for prevalent type 2 diabetes or treatment with any LMAs. Results are presented by sex across all racial/ethnic minority groups, and all comparisons are to NHWs. Using logistic regression models with the product terms, we tested whether race/ethnicity is a significant effect modifier of the association between dyslipidemia subtypes and CVD after adjusting for common CVD risk factors. Because of the multiple comparisons included in this descriptive study, 99.9% confidence intervals are reported when appropriate. Statistical analyses were performed using SAS 9.3 (Cary, NC).
Results
169
,430 patients were included in the analysis with patient characteristics reported in Table 1 .
Mexicans and every Asian subgroup except for Japanese were younger than NHWs. With the exception of Filipino women, all Asian subgroups had significantly lower mean BMI compared to NHW, whereas Mexicans and Black/Africans had higher mean BMI. Filipino, Korean, Vietnamese, and Black/African men were more likely to have ever smoked, and all Asian and Mexican women were less likely to have ever smoked, compared to NHW. Three Asian subgroups (Asian Indians, Filipinos, and Japanese) as well as Mexicans and Black/Africans had higher rates of type 2 diabetes compared to NHWs.
Age-adjusted prevalence rates of dyslipidemia subtypes and LDL-lowering treatment across racial/ethnic subgroups are described in Table 2 . Filipino and Mexican women had the highest prevalence rates of both high LDL-C and high TG. With regards to low HDL-C, Asian appropriate. Statistical analyses were performed using SAS 9.3 (Cary, NC).
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Me Me exi xi xica ca cans ns a a and nd nd e ev v very ry ry A A Asi i ian an sub ub u gr gr grou ou oup p p ex ex xce ce cept pt pt for or or J Ja a apa pa ane e ese e e w w wer er re e e yo yo oun un unge ge ger r r th th han an n N N NHW HW HWs s s. Wi Wi With th t the he he a a exception of f F F Fil il ilip ip pin in ino o o wo wo wome me men, n, n, a all ll ll A A Asi si sian n n s sub ub ubgr gr grou ou oups ps p h h had ad a s s sig ig igni ni n fi fi f ca ca cant nt n ly y y l low ow ower er er m m mea ea an n n BM BM BMI I I compared Adjusted odds ratios by race/ethnicity and sex were estimated from the multivariable logistic regression models as described previously and reported for each dyslipidemia subtype (Figure 1) . Older (age >55 years) and overweight women were more likely to have combined dyslipidemias. Having ever smoked was associated with increased odds of having high LDL-C and high TG. After adjustment for patient characteristics, racial/ethnic differences among women were more pronounced for high LDL-C and low HDL-C, primarily because Asian women were younger and had lower rates of smoking and obesity. Asian Indian, Filipino and Vietnamese women had higher risk of possessing all three dyslipidemia subtypes. Mexican women and every female Asian subgroup (except Japanese women) had increased risk of having a combined Mexican (47.8%) men had the highest prevalence rates of low HDL-C whereas Ja Ja apa pa ane e ese se se m m men en e Similar to women, overweight men or men who had ever smoked had higher odds of having multiple dyslipidemia subtypes. For men, older age (>55 years) and HMO insurance (versus PPO insurance) were significantly associated with greater odds of high LDL-C.
Multivariable adjustment did not attenuate racial/ethnic differences in dyslipidemia for men.
Odds ratios for each dyslipidemia subtype were generally similar for men compared to women;
however, racial/ethnic differences for low HDL-C were smaller. Asian Indian men had higher odds of possessing all three dyslipidemia subtypes, compared to NHWs. Every Asian subgroup and Mexican men had increased risk for high TG while Black/African men had lower risk compared to NHWs. Figure 2 summarize racial/ethnic differences in dyslipidemia prevalence in patients with and without a history of CVD. The overall prevalence of CVD within the cohort was approximately 5%. The low number of patients with CVD made it difficult to compare dyslipidemia profiles among race/ethnic groups in those with CVD due to wide confidence intervals; only slight attenuation in prevalence odds ratios was seen in those without a history of CVD compared to the original cohort. Despite the low overall prevalence of CVD, some significant racial/ethnic differences in dyslipidemia profiles were still seen among these patients.
Asian Indian men continued to have higher odds of having all three dyslipidemia subtypes, and were the only group male or female to have increased odds of high LDL-C compared to NHW men. Asian Indian women and men as well as Chinese women had greater odds of having low HDL-C compared to NHW women and men. Finally, Chinese and Filipino men and women, Japanese women, and Asian Indian men had greater odds of having high TG compared to NHWs, while African American women were the only group to have significantly lower odds of compared to NHWs. Figure 2 summarize racial/ethnic differences in dyslipidemia prevalence in pa ati ti ien en ents ts ts w w wit it ith h h and d d w wi without a history of CVD. The e e ov ov overall prevalen nce c c o of f f C CV CVD within the cohort w was s s ap a proxim mat ate el e y y y 5% 5% 5%. T T The he he l l lo ow ow n n nu um umbe be er of f f p patie en nt t ts w w wit it th h CV CV CVD D ma made de i i it di diff ff fic ic icul ult t to to to c c com om mp pa pare re e dy dysl sl slip ip pid id i em em mia ia ia p pro ro ofi ile les s am am mon ong g ra race ce ce/e /e /et th thn ni nic c gr gr gro o oups ps ps i in n n t t tho ho ose se e w w wi it ith h h CV CV CVD D D du du d e e t to to w w wid id de e e co co on nf nfid d den n nce ce n ntervals; onl nly y y sl sl s ig ig ght ht ht a a att tt ten enua ua uati ti tion n n in in i p p pre reva va v le le lenc nc nce e e od od odds ds d r r rat atio io ios s wa wa was s s se se seen n n i in n n th th thos os ose e e wi wi w th th thou ou out t t a a history of f f high TG. We tested for formal interaction between each dyslipidemia subtype and race/ethnicity on prevalent CVD and found no significant interaction (p values of the product terms in the model are 0.11, 0.18 and 0.36 for high LDL-C, low HDL-C and high TG, respectively).
We conducted additional analyses (see supplemental appendix) to examine prevalence odds ratios for dyslipidemia subtypes after adjusting the multivariable model for: 1) prevalent type 2 diabetes and 2) treatment with lipid modifying (LMAs) and LDL-lowering (LLAs) agents (supplemental figures 1 and 2). Type 2 diabetes was positively associated with all three dyslipidemia subtypes with only slight attenuation of the observed racial/ethnic differences.
Similarly, adjusting for treatment status with any lipid lowering medication did not significantly change observed racial/ethnic differences in either low HDL-C or high TG. However, there were notable differences in the prevalence odd ratios for high LDL-C by race/ethnicity. Finally, we also examined the prevalence of isolated HDL-C, and in men only found significantly higher prevalence odds ratios for Asian Indians (OR 1.72, CI 1.50-1.98) compared with NHWs (supplemental figure 3). For women, higher prevalence odds ratios for isolated HDL-C were found for Asian Indians, Chinese, and Vietnamese as well as Mexicans and Black/AfricanAmerican women.
Discussion
To our knowledge, this is the first study to examine dyslipidemia prevalence across all major racial/ethnic subgroups in the United States. Our findings indicate that there are marked differences in the prevalence of dyslipidemia subtypes among racial/ethnic subgroups. Most of the minority racial/ethnic subgroups studied, particularly women, had increased prevalence of low HDL-C and elevated TG. Chinese men had lower odds of having high LDL-C, Japanese change observed racial/ethnic differences in either low HDL-C or high TG. How wev ev ever e e , , th th ther er ere e e we we w re notable differences in the prevalence odd ratios for high LDL-C by race/ethnicity. for Asian Indians, 16, 19 and higher levels of HDL-C for Japanese. 16 A large international metaanalysis conducted by Huxley et al. demonstrated a higher prevalence of isolated low HDL-C in Asians, which was associated with increased risk of coronary heart disease when compared to non-Asians. 13 The global case-control INTERHEART study found that there were a higher proportion of Asian cases and controls with LDL-C levels <100mg/dl compared to non-Asians. 16 Our cross-sectional analysis found an increased prevalence of high LDL-C for Asian
Indians, Filipinos and Vietnamese, and an increased prevalence of high TG for all Asian American subgroups. These findings reflect important and clinically relevant differences in diet and physical activity for Asians living in the U.S. as a result of immigration and acculturation. for Asian Indi di ian an ans, s, s, 16 16 16,19 19 19 a and n n h h hig ig ighe e er r r le leve ve v ls ls s o o of f f HD HD HDL-L-L C C C fo fo for r Ja Ja Japa pa pane ne nese se se. . 16 16 16 A A A l l lar ar arge ge ge i i int nt n er er erna na nati ti tion on onal a meta-
The Ni-Hon-San study demonstrated the effects of immigration and acculturation, finding that CHD and stroke mortality rates in Hawaii were intermediate between higher rates of stroke in Japan and higher rates of CHD in California. 31 The Ni-Hon-San study highlights the importance of studying Asian Americans specifically, since risk factor and disease prevalence may differ from those in the native Asian populations. When compared with international data these findings demonstrate that triglyceride levels are more sensitive and susceptible to environmental influences associated with immigration and acculturation (i.e. changes in diet, decreased physical activity, weight gain) than HDL-C. Chandalia et al. found that HDL-C levels were uniformly lower in Asian Indian women living in both the U.S. and India, but TG levels were higher only for those living in the U.S. 19 Our research is congruent with previous evidence 32 on the relative genetic and environmental contributions to triglyceride and HDL-C levels, and extends this observation to immigrant Asian populations in the U.S. Better understanding of these contributions may provide better insight in how to direct and improve prevention efforts in minority groups.
The variation in dyslipidemia prevalence among minority groups appears to correlate with the rates of CHD. Among Asian Americans, Asian Indians and Filipinos have consistently been shown to have increased risk for CHD 5, 6 with higher mortality rates than other racial/ethnic groups in the U.S. 33, 34 In contrast, CHD incidence and mortality rates are lower for Chinese and Japanese, 35, 36 which may be explained in part by the protective effects of having low LDL-C and high HDL-C in these subgroups. 16 Similar to Asian Americans, Mexican Americans who exhibit combined dyslipidemia, particularly the atherogenic high TG/low HDL profile, appear to have increased CHD risk. The Hispanic Community Health Study/Study of Latinos found increased CHD risk (self-reported) among Hispanic/Latino participants with hypercholesterolemia. 21 The for those living in the U.S. 19 Our research is congruent with previous evidence 32 2 o o on n th th he e re re rela la lati ti tive ve genetic and environmental contributions to triglyceride and HDL-C levels, and extends this ob bse se serv rv vat at atio io ion n n to to to imm mm mmig i rant Asian populations in t th he he U U.S. Better und nd ders sta ta an nd nding of these co on nt ntri r butions ma ma ay pr ro ov ovid id de e e be be bett tt tter er i i ins ns nsig ight ht in h ho how to o o d dire e ect ct t a an nd nd i im mp pr ro ove ve p pr re eve ve ent nt tio ion n ef ef ffo fo for r rts s in in in mi mi ino no n ri ri rity ty ty g g gro ro rou up ups. s.
The va va ari ri riat at tio io ion n n in in i dys ys ysli li ipi p p de de demi mi mia a a pr pr prev ev val al alen en nce ce c a am m mon on o g g g mi mi mino no n ri ri rity ty ty g g gro ro roup up ups s s ap ap appe pe ear ar ars s s to to o c c cor o relate INTERHEART study also found abnormal lipids to be strongly associated with increased risk of acute myocardial infarction in subjects from Latin America. 37 However, for African Americans who have relatively benign dyslipidemia patterns (low LDL-C, high HDL-C, low TGs), higher prevalence rates of hypertension, diabetes, and obesity may play a greater role in explaining CHD risk. 3, 21 Rates of hypertension for African Americans are almost twice as high, compared to NHWs, 38 and blood pressure was shown to be more predictive of CHD in African American women than NHW women. 39 LDL-C has been the primary target of CVD prevention and treatment with statins being the most widely prescribed cholesterol-lowering medications in the U.S. 10, 40 The national prevalence of lipid-lowering medication for all adults is 15.5% (2007-2010 NHANES), 27 which is slightly lower than we found, most likely due to the older age of our cohort. Contrary to national findings, however, treatment rates were higher for the majority of minority groups, which may be a reflection of increased access to care for this insured population. The higher prevalence of elevated LDL-C seen among Asian Indians, Filipinos and Vietnamese may be an especially important target for CVD prevention in Asian Americans.
Asian and Mexican Americans, but not African Americans appear to possess the high TG/low HDL-C dyslipidemia pattern, which has been characterized as atherogenic and associated with insulin resistance/metabolic syndrome. 41, 42 There is currently a lack of specific treatment options for low HDL-C and elevated TG due to a lack of efficacy data. Lipid medications that specifically target TGs and HDL-C, such as fibrates and niacin, have demonstrated a reduction of CVD events in some trials but not in many others. [43] [44] [45] [46] [47] Guidelines for dyslipidemia management and treatment have largely been derived from clinical trials comprised of mostly NHW populations, which have often under-represented minority groups.
prevalence of lipid-lowering medication for all adults is 15.5% (2007-2010 NHA A ANE NE NES S) S), , 27 27 27 w w whi h hic ch s slightly lower than we found, most likely due to the older age of our cohort. Contrary to na ati ti ion on onal al al f f fin in indi di ding ngs, s, s h h ho owever, treatment rates were e e h hi h g g gher for the ma ma ajo j ri ity ty ty o o of minority groups, w whi ic ich may be e a a r re ef fle ect c ctio o on n n of of of in in incr cre ea eas se sed d d a a acce ess ss to c ca car re f f for or r t th h his s in ins su sur re red d p p pop pu pula la ati ti ion on. Th Th The e hi h h gh gh gher er r pr prev ev eval al alen en e ce ce e o o of f f el ele ev evat at a ed ed d L L LDL D -C -C -C s s see ee een n n am am mon on ong g g As As Asia ia i n n n In n ndi ia ians ns ns, , F Fi Fili li lipi pi p no no nos s s an an nd Vi Viet et etna na name me ese se se m m may y y b be e e an an n especially imp mp mpor or orta ta ant nt nt t tar ar arge g g t t t fo fo for r CV CV CVD D D pr pr rev ev even en enti ti t on on on i in n n As As A ia ian n n Am Am Amer er eric ic ican an ns. s. s
Future clinical trials should include minority subgroups to further examine the potential benefits of HDL-C and TG treatment for these groups specifically.
Study limitations include using data from a single geographic area (Northern California) with smaller sample sizes in the African American, Mexican, Korean and Vietnamese populations. However, this region has the most diversity in minority subgroups in the U.S. The study population is also insured and under-representative of the medically underserved, but these geographic and socioeconomic limitations also minimize unmeasured confounding between subgroups. Because clinical and administrative records rarely include any socioeconomic data on the individual level, this relative homogeneity in economic status improves the internal validity of our comparisons. We adjusted the significance level to p<0.001 to account for multiple comparisons. We were not able to include lifestyle information, such as physical activity or dietary habits for comparison between minority groups. As a cross-sectional analysis, we were unable to examine the temporal relationships between dyslipidemias and development of comorbidities such as cardiovascular disease. Finally, we could not account for patients who during the study period may have been started on LLAs for reasons other than high LDL (CVD, stroke, peripheral vascular disease, etc.), which may have overestimated prevalence rates. Our findings regarding high LDL-C must be interpreted with caution due to the inclusion of LLAs in our definition of the high LDL-C subtype. When stratified by treatment (supplemental figure 2), there are differences in the prevalence odds ratios by race/ethnicity for having high LDL-C lab test that are difficult to explain given our cross-sectional design. Unlike LDL-C, the racial/ethnic differences in prevalence odds ratios for having low HDL-C or high TG are consistent with and without medication adjustment, and therefore may offer unique opportunities for improving prevention efforts and further research in minority populations.
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Conclusion
Most minority subgroups have higher prevalence rates of dyslipidemia than do NHWs. Asian Indian, Filipino, Vietnamese women, and Asian Indian men stood out as Asian subgroups with increased risk of having combined dyslipidemias (high LDL-C, low HDL-C, and high TG).
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